Boehringer Ingelheim and Simcere collaborate on dual-target antibody for inflammatory bowel disease, targeting TL1A/IL23p19, to boost efficacy beyond current limits. Strengthened pipeline with new pre-clinic asset.

A recently developed bispecific antibody targeting TL1A and IL23p19 aims to address key drivers of disease pathogenesis in inflammatory bowel disease, potentially surpassing the efficacy limitations seen in current treatments. Boehringer has bolstered its inflammatory disease pipeline through a license and collaboration agreement for this promising pre-clinical asset, marking a significant addition to their portfolio. This novel antibody represents a potential first-in-class treatment, signaling a significant advancement in the field of inflammatory bowel disease treatment.